News

Swelling and fluid retention are common symptoms for individuals with transthyretin amyloid cardiomyopathy (ATTR-CM). This condition causes the heart muscle to…

In Las Vegas, Nevada, United States, DelveInsight's assessment reveals that globally, there are 10 key companies actively developing treatment therapies for AL…

NICE(UK): Acoramidis can be used, within its marketing authorisation, as an option to treat wild-type or hereditary transthyretin amyloidosis with cardiomyopathy in…

Impact of disease-modifying therapies on imaging parameters in cardiac amyloidosis: A systematic review and meta-analysis.

 I would like to attend…Live In Person in New OrleansSaturday, March 28, 20266:30-7:00 AM CDT: Registration & Breakfast7:00-8:00 AM CDT: SymposiumVirtually…

Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque- like…

Fresh funding backs a high-stakes attempt to do what current amyloidosis drugs still cannot: clear the buildup already damaging the heart.UK-based biotech Immutrin…

PurposeAmyloid positron emission tomography (PET) tracers are increasingly used to detect cardiac amyloidosis (CA). 11C-Pittsburgh compound B (PiB) and 1⁸F-…

Viz.ai has announced a partnership with Alnylam Pharmaceuticals to improve early identification and care coordination for patients with cardiac amyloidosis, a…

Join the CCS for the third and final installment of the Amyloid Education Series 2.0 in the upcoming webinar, ‘Cases and Clinical Conundrums in Amyloidosis…